Century Therapeutics stock (US15671W1045): Clinical progress in iPSC cell therapies

Century Therapeutics advances its allogeneic iPSC-derived therapies with recent preclinical data and partnerships, positioning it in the competitive cell therapy space for US investors.

Century Therapeutics, a clinical-stage biotechnology company, continues to develop induced pluripotent stem cell (iPSC) platforms for cancer immunotherapies. Recent preclinical studies highlighted potential efficacy in solid tumors, drawing attention from investors tracking innovative oncology treatments.

The company reported promising data from its CNTY-101 program targeting NK cell therapies, according to company IR as of 04/2026. Shares have shown volatility typical of biotech firms awaiting key trial readouts.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Century Therapeutics
• Sector/industry: Biotechnology / Cell Therapy
• Headquarters/country: United States
• Core markets: Oncology, Immunology
• Key revenue drivers: Clinical milestones, partnerships
• Home exchange/listing venue: Nasdaq (IPSC)
• Trading currency: USD

Century Therapeutics: core business model

Century Therapeutics focuses on developing allogeneic, iPSC-derived cell therapies for cancer and autoimmune diseases. The company's Allo-Evasion technology aims to create off-the-shelf treatments that evade immune rejection, a key challenge in cell therapy. This platform supports multiple product candidates, including natural killer (NK) cells and T-cell therapies.

Founded in 2018 and headquartered in Austin, Texas, the firm went public via Nasdaq in 2021. Its pipeline emphasizes solid tumors and hematologic malignancies, with CNTY-101 in Phase 1 trials for lymphoma as a lead asset, per IR site as of 05/2026.

Main revenue and product drivers for Century Therapeutics

Century Therapeutics generates milestones and upfront payments from collaborations, such as its partnership with Bristol Myers Squibb announced in 2023 for iPSC platforms. Pipeline progression drives value, with clinical data readouts serving as catalysts. The company reported a cash position of approximately $150 million as of Q1 2026 filings, supporting operations through 2027.

Key products include CNTY-101 (NK therapy for B-cell malignancies) and CNTY-102 (CAR-iNK for solid tumors). Preclinical advancements in 2026 underscore potency against tumor microenvironments, relevant for US biotech investors eyeing immunotherapy growth.

Industry trends and competitive position

The cell therapy sector has expanded rapidly, with iPSC approaches gaining traction for scalability over autologous methods. Competitors like Fate Therapeutics and Allogene Biotechnology pursue similar allogeneic strategies. Century's Allo-Evasion editing differentiates it by enhancing persistence in patients.

US market exposure is strong via Nasdaq listing and focus on prevalent cancers like lymphoma, which affect thousands annually. Sector funding remains robust despite macro pressures, per industry reports.

Why Century Therapeutics matters for US investors

As a Nasdaq-listed biotech, Century Therapeutics offers exposure to cutting-edge oncology innovations amid rising US healthcare spending on advanced therapies. Its iPSC platform addresses manufacturing scalability, a priority for FDA approvals and commercialization.

Investors benefit from potential milestone payments and buyout interest in the space, with historical deals like those in CAR-T setting precedents.

Conclusion

Century Therapeutics remains focused on advancing its iPSC-derived therapies amid a dynamic biotech landscape. Recent preclinical progress and partnerships highlight ongoing momentum, though clinical risks persist. US investors may track upcoming trial data for insights into its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.